UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 1029-13
Program Prior Authorization/Notification
Medication Enbrel® (etanercept)
P&T Approval Date 1/2007, 6/2008 , 4/2009, 6/2009, 12/2009, 7/2010, 11/2010, 7/2011,
11/2011, 7/2012, 11/2012, 2/2014, 2/2015, 3/2016, 3/2017, 3/2018,
3/2019, 3/2020, 3/2021, 3/2022, 3/2023, 7/2023, 10/2024
Effective Date 1/1/2025
1. Background:
Enbrel (etanercept) is a tumor necrosis factor (TNF) blocker indicated for the treatment of
rheumatoid arthritis (RA), polyarticular juvenile idiopathic arthritis (PJIA) in patients 2 years of
age or older, psoriatic arthritis (PsA) in patients 2 years of age or older, ankylosing spondylitis
(AS), and plaque psoriasis (PsO) in patients 4 years or older.1
2. Coverage Criteriaa:
A. Rheumatoid Arthritis (RA)
1. Initial Authorization
a. Enbrel will be approved based on both of the following criteria:
(1) Diagnosis of moderately to severely active rheumatoid arthritis
-AND-
(2) Patient is not receiving Enbrel in combination with another targeted
immunomodulator [e.g., Cimzia (certolizumab), Simponi (golimumab),
Orencia (abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant
(baricitinib), Rinvoq (upadacitinib)]
Authorization will be issued for 12 months.
2. Reauthorization
a. Enbrel will be approved based on both of the following criteria:
(1) Documentation of positive clinical response to Enbrel therapy
-AND-
(2) Patient is not receiving Enbrel in combination with another targeted
immunomodulator [e.g., Cimzia (certolizumab), Simponi (golimumab),
Orencia (abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant
(baricitinib), Rinvoq (upadacitinib)]
© 2024 UnitedHealthcare Services, Inc.
1
Authorization will be issued for 12 months.
B. Polyarticular Juvenile Idiopathic Arthritis (PJIA)
1. Initial Authorization
a. Enbrel will be approved based on both of the following criteria:
(1) Diagnosis of moderately to severely active polyarticular juvenile idiopathic
arthritis
-AND-
(2) Patient is not receiving Enbrel in combination with another targeted
immunomodulator [e.g., Cimzia (certolizumab), Simponi (golimumab),
Orencia (abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant
(baricitinib), Rinvoq (upadacitinib)]
Authorization will be issued for 12 months.
2. Reauthorization
a. Enbrel will be approved based on both of the following criteria:
(1) Documentation of positive clinical response to Enbrel therapy
-AND-
(2) Patient is not receiving Enbrel in combination with another targeted
immunomodulator [e.g., Cimzia (certolizumab), Simponi (golimumab),
Orencia (abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant
(baricitinib), Rinvoq (upadacitinib)]
Authorization will be issued for 12 months.
C. Psoriatic Arthritis (PsA)
1. Initial Authorization
a. Enbrel will be approved based on both of the following criteria:
(1) Diagnosis of active psoriatic arthritis
-AND-
(2) Patient is not receiving Enbrel in combination with another targeted
immunomodulator [e.g., Cimzia (certolizumab), Simponi (golimumab),
Orencia (abatacept), adalimumab, Stelara (ustekinumab), Skyrizi
(risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz
© 2024 UnitedHealthcare Services, Inc.
2
(ixekizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq
(upadacitinib), Otezla (apremilast)]
Authorization will be issued for 12 months.
2. Reauthorization
a. Enbrel will be approved based on both of the following criteria:
(1) Documentation of positive clinical response to Enbrel therapy
-AND-
(2) Patient is not receiving Enbrel in combination with another targeted
immunomodulator [e.g., Cimzia (certolizumab), Simponi (golimumab),
Orencia (abatacept), adalimumab, Stelara (ustekinumab), Skyrizi
(risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz
(ixekizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq
(upadacitinib), Otezla (apremilast)]
Authorization will be issued for 12 months.
D. Plaque Psoriasis
1. Initial Authorization
a. Enbrel will be approved based on both of the following criteria:
(1) Diagnosis of chronic moderate to severe plaque psoriasis
-AND-
(2) Patient is not receiving Enbrel in combination with another targeted
immunomodulator [e.g., Cimzia (certolizumab), Simponi (golimumab),
Orencia (abatacept), adalimumab, Stelara (ustekinumab), Skyrizi
(risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz
(ixekizumab), Siliq (brodalumab), Ilumya (tildrakizumab), Xeljanz
(tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla
(apremilast)]
Authorization will be issued for 12 months.
2. Reauthorization
a. Enbrel will be approved based on both of the following criteria:
(1) Documentation of positive clinical response to Enbrel therapy
-AND-
© 2024 UnitedHealthcare Services, Inc.
3
(2) Patient is not receiving Enbrel in combination with another targeted
immunomodulator [e.g., Cimzia (certolizumab), Simponi (golimumab),
Orencia (abatacept), adalimumab, Stelara (ustekinumab), Skyrizi
(risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz
(ixekizumab), Siliq (brodalumab), Ilumya (tildrakizumab), Xeljanz
(tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla
(apremilast)]
Authorization will be issued for 12 months.
E. Ankylosing Spondylitis (AS)
1. Initial Authorization
a. Enbrel will be approved based on both of the following criteria:
(1) Diagnosis of active ankylosing spondylitis
-AND-
(2) Patient is not receiving Enbrel in combination with another targeted
immunomodulator [e.g., Cimzia (certolizumab), Simponi (golimumab),
Orencia (abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant
(baricitinib), Rinvoq (upadacitinib)]
Authorization will be issued for 12 months.
2. Reauthorization
a. Enbrel will be approved based on both of the following criteria:
(1) Documentation of positive clinical response to Enbrel therapy
-AND-
(2) Patient is not receiving Enbrel in combination with another targeted
immunomodulator [e.g., Cimzia (certolizumab), Simponi (golimumab),
Orencia (abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant
(baricitinib), Rinvoq (upadacitinib)]
Authorization will be issued for12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
© 2024 UnitedHealthcare Services, Inc.
4
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
• Supply limits and/or Step Therapy may be in place.
4. References:
1. Enbrel [package insert]. Thousand Oaks, CA: Immunex Corp.; October 2023.
Program Prior Authorization/Notification – Enbrel (etanercept)
Change Control
2/2014 Background updated. Concomitant therapy criterion condensed to list
four biologic DMARDs and revised to include Xeljanz. Reauthorization
criteria revised to standard verbiage and to include concomitant therapy
criterion. Extended reauthorization duration to 24 months.
2/2015 Annual review with no change to coverage criteria. Minor reformatting.
Updated clinical rules, background and references.
3/2016 Annual review. Added Otezla (apremilast) to the list of medications
that the patient should not be receiving while on Enbrel therapy for
plaque psoriasis and psoriatic arthritis. Added “polyarticular” to
juvenile idiopathic arthritis. Updated reference.
3/2017 Annual review with no change to coverage criteria. Updated
background and references.
3/2018 Annual review with no change to coverage criteria. Updated
references.
3/2019 Annual review. Added Olumiant (baricitinib) to list of medications that
patient should not be receiving while on Enbrel therapy for rheumatoid
arthritis. Updated background.
3/2020 Annual review. Added Rinvoq (upadacitinib) to list of medications that
patient should not be receiving while on Enbrel therapy for RA and
Skyrizi (risankizumab) for PsO. Updated background.
3/2021 Annual review. Updated reauthorization approval length. Updated
reference.
3/2022 Annual review. Updated references.
3/2023 Annual review. Changed Humira examples to adalimumab and added
Rinvoq as a JAKI example. Added state mandate footnote. Updated
background and reference.
7/2023 Updated not receiving in combination language to targeted
immunomodulator and updated examples.
10/2024 Annual review with no change to coverage criteria. Updated
background and reference.
© 2024 UnitedHealthcare Services, Inc.
5